Archive
2021, Volume 5
2020, Volume 4
2019, Volume 3
2018, Volume 2
2017, Volume 1




Volume 4, Issue 2, December 2020, Page: 92-95
Report of a Case of Primary Signet-ring Cell Carcinoma of the Bladder and Review of the Literature
Baiyun Gao, Department of Urology, The First Affiliated Hospital, Jinan University, Guangzhou, China
Guo Chen, Department of Urology, The First Affiliated Hospital, Jinan University, Guangzhou, China
Yutong Li, Department of Urology, The First Affiliated Hospital, Jinan University, Guangzhou, China
Bin Pan, Department of Urology, The First Affiliated Hospital, Jinan University, Guangzhou, China
Received: Dec. 4, 2020;       Accepted: Dec. 14, 2020;       Published: Dec. 22, 2020
DOI: 10.11648/j.ijcu.20200402.23      View  45      Downloads  32
Abstract
Primary signet-ring cell carcinoma of the bladder is a relatively rare tumor that progresses rapidly and has an extremely poor prognosis. We report a case of primary signet-ring cell carcinoma of the bladder. The patient underwent transurethral holmium laser lithotripsy for bladder calculi in another hospital, and a bladder tumor was found intraoperatively. Bladder tumor biopsy revealed infiltrating high-grade urothelial carcinoma with adenoid differentiation and invasion to the muscular layer. Gastrointestinal endoscopy ruled out other possible sources of tumor, and the patient was admitted to our hospital for treatment in October 2018. Cystoscopy revealed a large round mass in the trigone and right bladder wall, without probing the pedicle of the mass. After radical cystectomy, postoperative pathology showed signet-ring cell carcinoma, which infiltrated the full-thickness of the bladder wall, and cancer emboli were found in vasculature. The prostate gland and bilateral seminal vesicle were involved. After surgery, the patient did not receive any follow-up treatment due to personal factors. The Computed Tomography (CT) review at the 3rd month showed no tumor recurrence or metastasis, and the CEA review at the 6th month was 6790.2 ng/ml, considering that tumor metastasis had occurred. The patient was followed up for 9 months after surgery, and the postoperative survival time was more than 8 months. The prognosis of primary signet-ring cell carcinoma of the bladder is poor and most patients are in advanced stage at the time of diagnosis. Chemotherapy and radiotherapy have poor effect on it. Usually only total cystectomy may bring some hope to patients. Thus, early diagnosis and treatment are crucial.
Keywords
Signet-ring Cell Carcinoma, Bladder, Urothelial Carcinoma, Therapy, Prognosis
To cite this article
Baiyun Gao, Guo Chen, Yutong Li, Bin Pan, Report of a Case of Primary Signet-ring Cell Carcinoma of the Bladder and Review of the Literature, International Journal of Clinical Urology. Vol. 4, No. 2, 2020, pp. 92-95. doi: 10.11648/j.ijcu.20200402.23
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. (2016). The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. European urology 70 (1): 106-19.
[2]
D J, S Q, K J, X Z, Q C, L Y, et al. (2020). Signet-Ring Cell Carcinoma as an Independent Prognostic Factor for Patients With. Front Oncol 2020 May 15; 10: 653.
[3]
Wang J, Wang FW. (2011). Clinical Characteristics and Outcomes of Patients with Primary Signet-Ring Cell Carcinoma of the Urinary Bladder. Urologia Internationalis 86 (4): 453-60.
[4]
Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, et al. (2019). What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. European urology oncology 2 (6): 625-42.
[5]
Natale C, Leinwand GZ, Chiang J, Silberstein JL, Krane LS. (2019). Reviewing the Demographic, Prognostic, and Treatment Factors of Primary Adenocarcinoma of the Bladder: A SEER Population-based Study. Clinical genitourinary cancer 17 (5): 380-8.
[6]
Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, et al. (2019) Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations. Hum Pathol 85: 1-9.
[7]
Bouhajja L, Farah F, Garbouj N, Rammeh S. (2019). Primary signet-ring cell carcinoma of the urinary bladder: A report of two cases. La Tunisie medicale 97 (1): 167-9.
[8]
Akamatsu S, Takahashi A, Ito M, Ogura K. (2010). Primary signet-ring cell carcinoma of the urinary bladder. Urology 75 (3): 615-8.
[9]
Wang J, Wang FW, Kessinger A. (2012). The impact of signet-ring cell carcinoma histology on bladder cancer outcome. World journal of urology 30 (6): 777-83.
[10]
Kinra P, Rashmi SP, Alam A, Singh H, Dash SC. (2017). Primary signet cell adenocarcinoma of bladder. Indian journal of pathology & microbiology 60 (4): 584-6.
[11]
Chiesa-Vottero A. (2020). CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 39 (2): 170-7.
[12]
Yang C, Sun L, Zhang L, Zhou L, Zhao M, Peng Y, et al. (2018). Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin. 42 (2): 160-71.
[13]
Lendorf M, Dohn L, Á Dunga B, Loya A, Pappot HJSjou. (2018). An updated review on primary signet-ring cell carcinoma of the urinary bladder and report of a case. 52 (2): 87-93.
[14]
Jue JS, Koru-Sengul T, Moore KJ, Miao F, Alameddine M, Nahar B, et al. (2018). Sociodemographic and survival disparities for histologic variants of bladder cancer. The Canadian journal of urology 25 (1): 9179-85.
[15]
Jayarajah U, Fernando DMH, Herath KB, de Silva MVC, Goonewardena SAS. (2017). Primary Signet-Ring Cell Adenocarcinoma of the Urinary Bladder Treated with Partial Cystectomy: A Case Report and Review of the Literature. Case reports in urology 2017: 6829692.
[16]
Hamakawa T, Kojima Y, Naiki T, Kubota Y, Yasui T, Tozawa K, et al. (2013). Long-term survival of a patient with invasive signet-ring cell carcinoma of the urinary bladder managed by combined s-1 and Cisplatin adjuvant chemotherapy. Case reports in urology 2013: 915874.
Browse journals by subject